Septerna appoints Gil Labrucherie as CFO effective Jan 6, 2025; interim CFO Ran Xiao resigns

Septerna, Inc.

Gil Labrucherie appointed CFO, principal financial and accounting officer, effective Jan 6, 2025.
Labrucherie brings 25+ years biotech experience, most recently CFO of Acelyrin and Nektar Therapeutics.
Compensation includes $485k base salary, 40% target bonus, and stock option for 222,000 shares.
Interim CFO Ran Xiao resigns from CFO role but remains VP of Finance and Business Operations.
Labrucherie has raised over $1.5B in equity and generated $1B+ in strategic partnering value.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gil M. Labrucherie

Chief Financial Officer

SEPN · Septerna, Inc.

Effective: 2025-01-06
Filed: January 6, 2025, 6:59 PM ET

On December 23, 2024, the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) appointed Gil M. Labrucherie as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, in each case, effective as of January 6, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gil M. Labrucherie was appointed as Chief Financial Officer at Septerna, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On December 23, 2024, the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) appointed Gil M. Labrucherie as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, in each case, effective as of January 6, 2025.

View on SEC.gov

Septerna, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-001834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.